✦ LIBER ✦

Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era

✍ Scribed by Wouter Jacobs; Anco Boonstra; Monika Brand; Daniel M. Rosenberg; Berthold Schaaf; Pieter E. Postmus; Anton Vonk Noordegraaf

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Usefulness of first-line combination the

✍ Kristina Kemp; Laurent Savale; Dermot S. O'Callaghan; Xavier Jaïs; David Montani 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 580 KB

Survival in patients with pulmonary arte

✍ V. V. McLaughlin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

A randomized open label study comparing

✍ Mazzanti, G.; Albini, A.; Palazzini, M.; Monti, E.; Bachetti, C.; Rinaldi, A.; C 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 75 KB

Long-Term Outcome of Bosentan Treatment

✍ Reda E. Girgis; Stephen C. Mathai; Jerry A. Krishnan; Fredrick M. Wigley; Paul M 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Long-term Follow-up After Conversion fro

✍ Roger F. Johnson; James E. Loyd; Amy L. Mullican; Cynthia A. Fink; Ivan M. Robbi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 79 KB

PCV117 COST-UTILITY OF BOSENTAN IN THE F

✍ EJ Soini; MD Stevenson; JA Martikainen; RL Akehurst 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB